CRISPR Base Editing Delivery Technology — PatSnap Eureka
CRISPR Base Editing Delivery Technology Landscape
Base editors install precise point mutations without double-strand DNA breaks — but their large fusion protein size makes delivery the defining bottleneck for clinical translation. This report maps viral, non-viral, and emerging delivery modalities from patent filings and literature spanning 2015–2025.
Two Foundational Classes, One Critical Delivery Challenge
CRISPR base editing systems couple a catalytically impaired Cas protein (dead Cas9 or Cas9 nickase) with a nucleobase deaminase enzyme to effect programmable single-nucleotide conversions at targeted genomic loci. The two foundational classes are Cytosine Base Editors (CBEs), which convert C to T (or C·G to T·A base pairs) via cytidine deaminase activity, and Adenine Base Editors (ABEs), which convert A to G (or A·T to G·C base pairs) via engineered adenosine deaminase activity.
Because base editing avoids double-strand DNA breaks, the editing window is narrower and on-target precision is substantially improved relative to classical CRISPR-Cas9 nuclease approaches. However, the large molecular size of base editor fusion proteins — which can exceed the AAV packaging capacity of approximately 4.7 kb — is the central delivery challenge that has driven innovation across viral, lipid nanoparticle (LNP), and protein-based delivery modalities.
Beyond DNA base editors, RNA base editors fusing deaminases to Cas13 or Cas12a enable transient, non-heritable editing, expanding the delivery design space. The field also intersects with prime editing, which similarly requires DSB-free delivery of large reverse-transcriptase-fused constructs. This landscape draws on patent filings and literature published between 2015 and 2025 as indexed by PatSnap. External reference data from WIPO, NIH PubMed, and EPO Espacenet contextualises the global patent activity described below.
Three Distinct Phases of Base Editor Delivery Innovation
Within this dataset, publications and filings span approximately 2015–2025, revealing a clear progression from mechanistic foundations through diversification to clinical convergence.
Four Delivery Modality Clusters for CRISPR Base Editors
Patent filings and literature records from 2015–2025 organise into four distinct delivery technology clusters, each with characteristic trade-offs in size, immunogenicity, tropism, and clinical readiness.
AAV and Lentiviral Systems
Adeno-associated virus (AAV) remains the leading in vivo delivery platform in this dataset, favoured for its tissue tropism, low immunogenicity, and established clinical regulatory pathway. The ~4.7 kb packaging limit drives dual-AAV split-intein approaches and compact Cas variant development. Serotype selection enables tropism toward liver, muscle, and CNS targets. Lentiviral vectors (LVs) serve ex vivo cell therapy, with integrase-deficient variants (IDLVs) minimising oncogenicity risk during editing of primary T cells and HSCs.
AAV: leading in vivo platform per 2020 literatureLNPs, Polymeric Nanocarriers & Stimuli-Responsive Systems
Non-viral delivery via nanoparticles is the most heavily represented cluster in this dataset. Systems include liposomes, chitosan nanoparticles, poly(disulfide)s, and stimuli-responsive formulations. These deliver base editors as plasmid DNA, mRNA, or ribonucleoprotein (RNP) complexes. Poly(disulfide) copolymers containing diethylenetriamine and guanidyl moieties mediate efficient cellular uptake of plasmid, mRNA, and protein cargo formats, with intracellular glutathione-triggered degradation enabling cytosol release and minimising cytotoxicity. Stimuli-responsive platforms respond to pH gradients, redox conditions, light, and temperature.
Most represented cluster in datasetExtracellular Vesicles & Engineered Virus-Like Particles
Biological membrane-based delivery systems represent an emerging sub-cluster with distinct advantages in immunological stealth and tropism engineering. Extracellular vesicles (EVs) overcome immunogenicity, toxicity, and rapid degradation limitations that hamper synthetic nanoparticles in vivo. The 2022 Liu et al. engineered retroviral eVLP platform systematically optimised gag-cargo stoichiometry and cleavable linker engineering to create an efficient, safe base editor delivery vehicle for somatic editing — explicitly extensible to other CRISPR payloads. pH- and light-triggered endosomal escape strategies are critical for cytoplasmic delivery of base editor RNPs.
Clearest emerging direction per 2022 literatureBacterial Vectors & DNA Nanostructures
Sivec Biotechnologies has filed patents across WO, CA, and AU jurisdictions (2020–2022) for a bacterial-mediated gene-editing delivery platform using invasive non-pathogenic bacteria harbouring prokaryotic expression cassettes for CRISPR payloads to transfect eukaryotic target cells — circumventing size and immunogenicity constraints of both viral vectors and synthetic nanoparticles. Separately, self-assembled DNA nanostructures act as modular, addressable scaffolds for directing CRISPR/Cas spatial positioning and improving delivery precision, particularly relevant for base editor systems requiring accurate nuclear localisation.
Most patent-protected non-viral non-nanoparticle platformInnovation Phase Distribution & Application Domain Coverage
Visual summary of delivery technology activity across innovation phases and application domains, derived from patent and literature records in this dataset.
Publication Activity by Innovation Phase
The 2019–2022 Development phase contains the largest cluster of retrieved records, signalling rapid diversification of delivery modalities.
Application Domain Coverage
Therapeutic genome editing of monogenic diseases represents the largest application cluster; agricultural and ex vivo cell therapy are also prominent.
Multi-Jurisdictional Patent Activity Across Emerging & Established Markets
| Assignee | Jurisdiction(s) | Filing Period | Technology Focus | Status |
|---|---|---|---|---|
| Sivec Biotechnologies, LLC | WO, CA, AU | 2020–2022 | Bacterial-mediated gene-editing delivery platform | Active / Pending |
| Osaka University | BR | 2020 | CRISPR-Cas3 eukaryotic editing system | Pending |
| Huazhong Agricultural University | CN | 2021 | Novel CRISPR/Cas9 gene editing vector | Inactive |
Five Innovation Vectors Shaping the Next Phase of Base Editor Delivery
Based on the most recent filings and publications (2022–2025) within this dataset, five directions are converging toward clinical and commercial relevance.
Compact & Synthetic Cas Variants
α-synCas, a fully synthetic PAMless Cas nuclease designed via Ancestral Sequence Reconstruction, is capable of cleaving dsDNA, ssDNA, and ssRNA. The MIDAS framework simultaneously improves PAM interactions and ssDNA catalytic pocket contacts in Cas12i, Cas12b, and CasX to substantially increase editing efficiency in human cells — both approaches targeting the packaging-size bottleneck directly.
Engineered Virus-Like Particles (eVLPs)
The 2022 Liu et al. retroviral eVLP platform — in which gag-cargo stoichiometry and cleavable linker engineering were systematically optimised — represents the clearest emerging direction for ex vivo and in vivo base editor delivery, offering transient protein-level delivery (reducing off-target exposure) with the tissue-targeting features of retroviral envelopes.
Five Actionable Signals for IP and R&D Strategy
Packaging size remains the defining constraint for viral base editor delivery. R&D investment in split-intein dual-AAV strategies, compact engineered Cas variants (Cas12i, Cas12f, synthetic α-synCas), and mRNA/LNP formats that bypass packaging limits entirely represents the highest-value engineering priority for in vivo therapeutic programs.
The RNP delivery format is gaining traction as the preferred modality for ex vivo cell therapy. Electroporation-based RNP delivery of base editors into HSPCs and T cells reduces off-target exposure duration and integrase-related genotoxicity risk, making it the format of choice for CAR-T and hemoglobinopathy programs nearing clinical development. PatSnap’s IP analytics platform can map the competitive freedom-to-operate landscape across these modalities.
Stimuli-responsive and tissue-targeted nanoparticle systems represent an underexploited IP space for in vivo oncology applications. Among retrieved results, this sub-field shows rapid publication growth (2020–2022) but limited patent filings, suggesting a window for IP capture by groups able to translate responsive nanoformulation designs into patentable delivery compositions. See how PatSnap customers identify such IP white spaces.
Sivec Biotechnologies’ bacterial delivery platform is the most patent-protected non-viral, non-nanoparticle delivery innovation in this dataset. Competitors and potential licensees should monitor its multi-jurisdictional prosecution status closely, particularly in WO, CA, and AU jurisdictions where prosecution appears active. Geographic diversification of CRISPR base editing patent activity — into India, Brazil, and continued CN agricultural filings — signals an expanding global competitive arena requiring freedom-to-operate assessments in emerging jurisdictions.
- Invest in split-intein dual-AAV and compact Cas variants to overcome the ~4.7 kb packaging limit
- Prioritise RNP electroporation for ex vivo HSC and T cell editing programs
- Monitor stimuli-responsive nanoformulation IP space — rapid publication growth with limited filings signals an IP capture window
- Track Sivec Biotechnologies’ WO, CA, AU prosecution status for bacterial delivery platform
- Assess freedom-to-operate in India, Brazil, and CN for base-edited agricultural and therapeutic applications
- Evaluate eVLP platforms for transient protein-level delivery combining low off-target exposure with retroviral envelope tropism
CRISPR Base Editing Delivery — Key Questions Answered
CRISPR base editing installs point mutations—C→T via cytosine base editors (CBEs) and A→G via adenine base editors (ABEs)—without inducing double-strand DNA breaks (DSBs), dramatically reducing unintended genomic rearrangements relative to classical CRISPR-Cas9 nuclease approaches.
The large molecular size of base editor fusion proteins can exceed the AAV packaging capacity of approximately 4.7 kb, which is the central delivery challenge that has driven innovation across viral, lipid nanoparticle (LNP), and protein-based delivery modalities.
Non-viral delivery includes lipid nanoparticles (LNPs), chitosan nanoparticles, poly(disulfide) copolymers, stimuli-responsive nanoformulations, extracellular vesicles (EVs), engineered virus-like particles (eVLPs), DNA nanostructures, and bacterial-mediated delivery platforms.
RNP (ribonucleoprotein) delivery of base editors offers reduced off-target editing due to transient Cas protein exposure. Electroporation-based RNP delivery into HSPCs and T cells reduces off-target exposure duration and integrase-related genotoxicity risk, making it the format of choice for CAR-T and hemoglobinopathy programs.
The dominant patent filer across multiple jurisdictions in this dataset is Sivec Biotechnologies, LLC (US-based), with filings in WO (2020), CA (2020), and AU (2022) for its bacterial delivery platform. Other filers include Osaka University (BR), Huazhong Agricultural University (CN), and Noida Institute of Engineering & Technology (IN, 2025).
Stimuli-responsive nanoformulations are nanocarriers engineered to respond to pH gradients, redox conditions, light, and temperature for triggered cargo release in target tissue microenvironments. This design direction is particularly relevant to tumor-targeted base editing, directly addressing off-tissue editing safety concerns in therapeutic applications.
PatSnap Eureka searches patents and research literature to answer instantly.